Biopharmaceutical Innovators Lead the Charge in Fight Against Coronavirus
Search
Filter by Category:
Results
A2A Pharmaceuticals is testing the use of selective covalent SARS-CoV-2 MPro inhibitors for COVID-19 patients.
Abbott has launched its third COVID-19 test, a laboratory-based antibody blood test that will ship in the U.S. beginning in April.
AbbVie has partnered with global authorities to support the use of HIV medicines to treat COVID-19.
Adaptive is leveraging its proprietary immune medicine platform to develop a therapeutic.
Agastiya Biotech is testing its anti-cancer small molecule AB001 for the treatment of COVID-19. 
Alexion has provided SOLIRIS as an experimental emergency treatment for a small number of patients with COVID-19 infection.
Algernon is testing Ifenprodil as therapeutic treatment for COVID-19, in addition to acute lung injury (ALI).
Alnylam Pharmaceuticals, Inc. has expanded its collaboration with Vir to advance RNAi therapeutics.
Altimunne is testing a single-dose Intranasal COVID-19 vaccine.
Amgen is leveraging its immunology and novel antibody therapy development to develop a therapeutic for COVID-19.
APEIRON Biologics AG has initiated a Phase II clinical trial of APN01 to treat COVID-19.
APEPTICO is researching solnatide IMP for the treatment of coronavirus.
Biotech Companies Are Responding Faster Than Ever to Emerging Health Threats
Biotech companies are responding faster than ever to emerging health threats
BIO Coronavirus Events

BIO virtually brought together 45 biotech innovators, government agencies, and leading academics to share information about their work to fight the coronavirus. 

In addition, view the BIO Europe Spring Combating Coronavirus virtual session.

Coronavirus
Dr. George Scangos Coronavirus Lead
Hear from BIO's Coronavirus Lead

George Scangos, Ph.D., President and Chief Executive Officer of Vir Biotechnology, has been selected to lead the Biotechnology Innovation Organization's response to Coronavirus (COVID-19). Dr. Scangos explains what this role means and why collaboration across the private, public and NGO sectors is vital in combating Coronavirus.

The Coronavirus Is No Match for Science, but We Must Finish the Job

Jim Greenwood in Morning Consult: The science is galloping forward, and collaboration between the public and private sectors is vital to combat the coronavirus. BIO is taking the lead to connect innovators with partners inside the federal government.

Coronavirus
Biopharmaceutical Innovators Are Leading The Charge In Fight Against Coronavirus

Here's a snapshot of how our industry is responding to the coronavirus.

BIO Members Are Working Around The Clock To Find Solutions To Combat Coronavirus

Learn about how the biopharmaceutical industry is responding to the coronavirus.

BIO/ BioCentury Survey: COVID-19 Impact on Clinical Trials

A joint survey from BIO and BioCentury finds companies are seeking guidance and regulatory flexibility, while at the same time moving to remote monitoring and telemedicine for ongoing trials. 

Biotech Leaders Hit the Airwaves to Talk About Industry’s Efforts to Eradicate Covid-19

As the novel coronavirus continues to spread, scientists and researchers are working around the clock to identify diagnostics, therapeutics and vaccines to help protect individuals and communities across the globe. 

BIO's Virtual Summit Recap

On March 24-25, 2020, BIO virtually convened more than 500 leaders from across industry, government, academia, and NGOs to assess the state of the pandemic and accelerate medical countermeasure solutions for COVID-19.

Vaccine Development, Manufacturing and Distribution During a Pandemic

Learn about how a COVID-19 vaccine will be procured and distributed during the public health emergency.